Case Series of Western Sydney's Experience with the Use of Mexiletine 150 mg Twice Daily as an Antiarrhythmic Drug in Ischaemic Cardiomyopathy Patients with Automated Implantable Cardioverter Defibrillators In-situ that Have Recurrent Ventricular Arrhythmias Refractory to Standard Treatment